TPT-260 DihydrochlorideThiophene thiourea derivative CAS# 2076-91-7 |
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2076-91-7 | SDF | Download SDF |
PubChem ID | 118797067 | Appearance | Powder |
Formula | C8H14Cl2N4S3 | M.Wt | 333.32 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | NSC55712; TPU-260 Dihydrochloride | ||
Solubility | DMSO : 100 mg/mL (300.01 mM; Need ultrasonic) | ||
Chemical Name | [5-(carbamimidoylsulfanylmethyl)thiophen-2-yl]methyl carbamimidothioate;chlorine | ||
SMILES | C1=C(SC(=C1)CSC(=N)N)CSC(=N)N.[Cl] | ||
Standard InChIKey | GXCPJDQXOZKZIJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H12N4S3.Cl/c9-7(10)13-3-5-1-2-6(15-5)4-14-8(11)12;/h1-2H,3-4H2,(H3,9,10)(H3,11,12); | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | TPT-260 2Hcl (TPU260 2Hcl) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this molecule as TPT-260. IC50 value: Target: |
TPT-260 Dihydrochloride Dilution Calculator
TPT-260 Dihydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0001 mL | 15.0006 mL | 30.0012 mL | 60.0024 mL | 75.003 mL |
5 mM | 0.6 mL | 3.0001 mL | 6.0002 mL | 12.0005 mL | 15.0006 mL |
10 mM | 0.3 mL | 1.5001 mL | 3.0001 mL | 6.0002 mL | 7.5003 mL |
50 mM | 0.06 mL | 0.3 mL | 0.6 mL | 1.2 mL | 1.5001 mL |
100 mM | 0.03 mL | 0.15 mL | 0.3 mL | 0.6 mL | 0.75 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
TPT-260 2Hcl (TPU260 2Hcl) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this molecule as TPT-260.
- H-Phe(4-NO2)-OH.H2O
Catalog No.:BCC3273
CAS No.:207591-86-4
- SB 203186 hydrochloride
Catalog No.:BCC5673
CAS No.:207572-69-8
- iso-PPADS tetrasodium salt
Catalog No.:BCC6749
CAS No.:207572-67-6
- Pirlindole mesylate
Catalog No.:BCC6764
CAS No.:207572-66-5
- (±)-1-(1,2-Diphenylethyl)piperidine maleate
Catalog No.:BCC6619
CAS No.:207461-99-2
- BTCP maleate
Catalog No.:BCC6753
CAS No.:207455-25-2
- L-693,403 maleate
Catalog No.:BCC5657
CAS No.:207455-21-8
- N-MPPP Hydrochloride
Catalog No.:BCC5672
CAS No.:207452-97-9
- Arteannuin N
Catalog No.:BCN4907
CAS No.:207446-92-2
- Arteannuin M
Catalog No.:BCN4906
CAS No.:207446-90-0
- Arteannuin L
Catalog No.:BCN4905
CAS No.:207446-89-7
- MR 16728 hydrochloride
Catalog No.:BCC6684
CAS No.:207403-36-9
- HS 014
Catalog No.:BCC5819
CAS No.:207678-81-7
- 5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)
Catalog No.:BCC4583
CAS No.:207679-81-0
- 1,7-Bis(4-hydroxyphenyl)-3-hydroxy-1,3-heptadien-5-one
Catalog No.:BCN6470
CAS No.:207792-17-4
- Propofol
Catalog No.:BCC9130
CAS No.:2078-54-8
- Isobavachalcone
Catalog No.:BCN5415
CAS No.:20784-50-3
- 4'-O-Methylbroussochalcone B
Catalog No.:BCN4908
CAS No.:20784-60-5
- Hemokinin 1 (mouse)
Catalog No.:BCC5774
CAS No.:208041-90-1
- Z-Ser(Bzl)-OH
Catalog No.:BCC2742
CAS No.:20806-43-3
- Strictosidine
Catalog No.:BCN2641
CAS No.:20824-29-7
- Nocistatin (bovine)
Catalog No.:BCC5703
CAS No.:208253-85-4
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- Zooxanthellabetaine A
Catalog No.:BCN1771
CAS No.:208256-89-7
Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.[Pubmed:28257497]
PLoS One. 2017 Mar 3;12(3):e0173303.
The widespread introduction of artemisinin-based combination therapy has contributed to recent reductions in malaria mortality. Combination therapies have a range of advantages, including synergism, toxicity reduction, and delaying the onset of resistance acquisition. Unfortunately, antimalarial combination therapy is limited by the depleting repertoire of effective drugs with distinct target pathways. To fast-track antimalarial drug discovery, we have previously employed drug-repositioning to identify the anti-amoebic drug, emetine dihydrochloride hydrate, as a potential candidate for repositioned use against malaria. Despite its 1000-fold increase in in vitro antimalarial potency (ED50 47 nM) compared with its anti-amoebic potency (ED50 26-32 uM), practical use of the compound has been limited by dose-dependent toxicity (emesis and cardiotoxicity). Identification of a synergistic partner drug would present an opportunity for dose-reduction, thus increasing the therapeutic window. The lack of reliable and standardised methodology to enable the in vitro definition of synergistic potential for antimalarials is a major drawback. Here we use isobologram and combination-index data generated by CalcuSyn software analyses (Biosoft v2.1) to define drug interactivity in an objective, automated manner. The method, based on the median effect principle proposed by Chou and Talalay, was initially validated for antimalarial application using the known synergistic combination (atovaquone-proguanil). The combination was used to further understand the relationship between SYBR Green viability and cytocidal versus cytostatic effects of drugs at higher levels of inhibition. We report here the use of the optimised Chou Talalay method to define synergistic antimalarial drug interactivity between emetine dihydrochloride hydrate and atovaquone. The novel findings present a potential route to harness the nanomolar antimalarial efficacy of this affordable natural product.
Original research paper. Characterization and taste masking evaluation of microparticles with cetirizine dihydrochloride and methacrylate-based copolymer obtained by spray drying.[Pubmed:28231047]
Acta Pharm. 2017 Mar 1;67(1):113-124.
Taste of a pharmaceutical formulation is an important parameter for the effectiveness of pharmacotherapy. Cetirizine dihydrochloride (CET) is a second-generation antihistamine that is commonly administered in allergy treatment. CET is characterized by extremely bitter taste and it is a great challenge to successfully mask its taste; therefore the goal of this work was to formulate and characterize the microparticles obtained by the spray drying method with CET and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate 1:2:1 copolymer (Eudragit E PO) as a barrier coating. Assessment of taste masking by the electronic tongue has revealed that designed formulations created an effective taste masking barrier. Taste masking effect was also confirmed by the in vivo model and the in vitro release profile of CET. Obtained data have shown that microparticles with a drug/polymer ratio (0.5:1) are promising CET carriers with efficient taste masking potential and might be further used in designing orodispersible dosage forms with CET.
Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria.[Pubmed:28271047]
Mol Genet Metab Rep. 2017 Feb 23;12:8-13.
Sapropterin dihydrochloride (BH4) reduces phenylalanine (Phe) levels and improves white matter integrity in a subset of individuals with phenylketonuria (PKU) known as "responders." Although prior research has identified biochemical and genotypic differences between BH4 responders and non-responders, cognitive and neural differences remain largely unexplored. To this end, we compared intelligence and white matter integrity prior to treatment with BH4 in 13 subsequent BH4 responders with PKU, 16 subsequent BH4 non-responders with PKU, and 12 healthy controls. Results indicated poorer intelligence and white matter integrity in non-responders compared to responders prior to treatment. In addition, poorer white matter integrity was associated with greater variability in Phe across the lifetime in non-responders but not in responders. These results underscore the importance of considering PKU as a multi-faceted, multi-dimensional disorder and point to the need for additional research to delineate characteristics that predict response to treatment with BH4.
Proposed phase 2/ step 2 in-vitro test on basis of EN 14561 for standardised testing of the wound antiseptics PVP-iodine, chlorhexidine digluconate, polihexanide and octenidine dihydrochloride.[Pubmed:28193164]
BMC Infect Dis. 2017 Feb 13;17(1):143.
BACKGROUND: Currently, there is no agreed standard for exploring the antimicrobial activity of wound antiseptics in a phase 2/ step 2 test protocol. In the present study, a standardised in-vitro test is proposed, which allows to test potential antiseptics in a more realistically simulation of conditions found in wounds as in a suspension test. Furthermore, factors potentially influencing test results such as type of materials used as test carrier or various compositions of organic soil challenge were investigated in detail. METHODS: This proposed phase 2/ step 2 test method was modified on basis of the EN 14561 by drying the microbial test suspension on a metal carrier for 1 h, overlaying the test wound antiseptic, washing-off, neutralization, and dispersion at serial dilutions at the end of the required exposure time yielded reproducible, consistent test results. RESULTS: The difference between the rapid onset of the antiseptic effect of PVP-I and the delayed onset especially of polihexanide was apparent. Among surface-active antimicrobial compounds, octenidine was more effective than chlorhexidine digluconate and polihexanide, with some differences depending on the test organisms. However, octenidine and PVP-I were approximately equivalent in efficiency and microbial spectrum, while polihexanide required longer exposure times or higher concentrations for a comparable antimicrobial efficacy. CONCLUSION: Overall, this method allowed testing and comparing differ liquid and gel based antimicrobial compounds in a standardised setting.